Annoor Awadasseid

Decheng, 313299, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal: Journal of medicinal chemistry

Published: July 03, 2026

Research Progress and Clinical Translation Challenges of Small-Molecule Inhibitors Targeting PD-L1.

Research Progress and Clinical Translation Challenges of Small-Molecule Inhibitors Targeting PD-L1.

Journal: ChemMedChem

Published: October 28, 2025

PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy.

PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy.

Journal: Bioorganic chemistry

Published: September 22, 2025

Small-Molecule Inhibitors Targeting PD-1/PD-L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects.

Small-Molecule Inhibitors Targeting PD-1/PD-L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects.

Journal: ChemMedChem

Published: August 28, 2025

Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms.

Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 11, 2025

Comparative druggability of PD-1/PD-L1 inhibitors (A56, HD10): Cross-species differences in PD-L1 exposure and efficacy.

Comparative druggability of PD-1/PD-L1 inhibitors (A56, HD10): Cross-species differences in PD-L1 exposure and efficacy.

Journal: Bioorganic & medicinal chemistry

Published: April 08, 2025

Novel PD-L1 Small-Molecule Inhibitors Advancing Cancer Immunotherapy.

Novel PD-L1 Small-Molecule Inhibitors Advancing Cancer Immunotherapy.

Journal: Anti-cancer agents in medicinal chemistry

Published: March 15, 2025

Progress in the Research and Development of Biphenyl Small Molecules Targeting PD-1/PD-L1 as Potential Antitumor Drug Candidates.

Progress in the Research and Development of Biphenyl Small Molecules Targeting PD-1/PD-L1 as Potential Antitumor Drug Candidates.

Journal: ChemMedChem

Published: March 04, 2025

Advances in cancer immunotherapy using small-molecular inhibitors targeting the PD-1/PD-L1 interaction.

Advances in cancer immunotherapy using small-molecular inhibitors targeting the PD-1/PD-L1 interaction.

Journal: Bioorganic & medicinal chemistry

Published: January 20, 2025

Antiproliferative activity of selenium-enriched coumarin derivatives on the SK-N-SH neuroblastoma cell line: Mechanistic insights.

Antiproliferative activity of selenium-enriched coumarin derivatives on the SK-N-SH neuroblastoma cell line: Mechanistic insights.

Journal: European journal of medicinal chemistry

Published: November 16, 2024

Design, synthesis and biological evaluation of novel TMPRSS2-PROTACs with florosubstituted 4-guanidino-N-phenylbenzamide derivative ligands.

Design, synthesis and biological evaluation of novel TMPRSS2-PROTACs with florosubstituted 4-guanidino-N-phenylbenzamide derivative ligands.

Journal: Bioorganic & medicinal chemistry

Published: September 12, 2024

Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors.

Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors.

Journal: European journal of medicinal chemistry

Published: May 31, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026